Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H17NO3 |
| Molecular Weight | 247.2897 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1C=CC2=CC=CC=C2N1C(=O)OCC
InChI
InChIKey=GKQLYSROISKDLL-UHFFFAOYSA-N
InChI=1S/C14H17NO3/c1-3-17-13-10-9-11-7-5-6-8-12(11)15(13)14(16)18-4-2/h5-10,13H,3-4H2,1-2H3
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Regulation of α₂-adrenoceptor gene expression by chronic lithium treatment in rat brain. | 2010-12 |
|
| Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors. | 2010-11 |
|
| Extrastriatal dopaminergic circuits of the Basal Ganglia. | 2010 |
|
| Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats. | 2009-08 |
|
| Action of dexmedetomidine on the substantia gelatinosa neurons of the rat spinal cord. | 2008-06 |
|
| Inhibition of reversed electron transfer and proton transport in the beef heart cytochrome bc1 complex by chemical modification. | 2007-03 |
|
| HPLC Method for Determination of Enantiomeric Purity of a Novel Respiratory Fluoroquinolone: WCK 1152. | 2007-02-06 |
|
| Dequalinium-induced protofibril formation of alpha-synuclein. | 2006-02-10 |
|
| Interactions between adenosine A(2a) and dopamine D2 receptors in the control of [(3)H]GABA release in the globus pallidus of the rat. | 2005-09-27 |
|
| Effect of chronic lithium treatment on the turnover of alpha2-adrenoceptors after chemical inactivation in rats. | 2004-12 |
|
| Effect of alpha 2-adrenoceptor blockade on lithium action in the rat brain. | 2003-12-19 |
|
| Aspartate-186 in the head group of the yeast iron-sulfur protein of the cytochrome bc1 complex contributes to the protein conformation required for efficient electron transfer. | 2003-12-08 |
|
| EMD 281014, a new selective serotonin 5-HT2A receptor antagonist. | 2003-07-25 |
|
| Lipid interaction of alpha-synuclein during the metal-catalyzed oxidation in the presence of Cu2+ and H2O2. | 2003-03 |
|
| A yeast mitochondrial ATPase inhibitor interacts with three proteins that are easy to dissociate from the mitochondrial inner membrane. | 2002-10 |
|
| Lead exposure and dorsomedial striatum mediation of fixed interval schedule-controlled behavior. | 2002-09 |
|
| alpha-Synuclein exhibits competitive interaction between calmodulin and synthetic membranes. | 2002-09 |
|
| Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. | 2002-09 |
|
| Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. | 2002-07 |
|
| Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. | 2002-03 |
|
| Dopamine receptors in the subthalamic nucleus are involved in the regulation of muscle tone in the rat. | 2002-01-14 |
|
| Carboxyl residues in the iron-sulfur protein are involved in the proton pumping activity of P. denitrificans bc(1) complex. | 2001-12-18 |
|
| Further characterization of 5-HT1A receptors in the goldfish retina: role of cyclic AMP in the regulation of the in vitro outgrowth of retinal explants. | 2001-03 |
|
| Differential protection and recovery of 5-HT1A receptors from N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) inactivation in regions of rat brain. | 2001-02 |
|
| Self-oligomerization and protein aggregation of alpha-synuclein in the presence of Coomassie Brilliant Blue. | 2001-01 |
|
| The role of the globus pallidus D2 subfamily of dopamine receptors in pallidal immediate early gene expression. | 2001 |
|
| The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors. | 1994-04 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
240-418-2
Created by
admin on Mon Mar 31 22:42:51 GMT 2025 , Edited by admin on Mon Mar 31 22:42:51 GMT 2025
|
PRIMARY | |||
|
27833
Created by
admin on Mon Mar 31 22:42:51 GMT 2025 , Edited by admin on Mon Mar 31 22:42:51 GMT 2025
|
PRIMARY | |||
|
60O971AN19
Created by
admin on Mon Mar 31 22:42:51 GMT 2025 , Edited by admin on Mon Mar 31 22:42:51 GMT 2025
|
PRIMARY | |||
|
DTXSID50871969
Created by
admin on Mon Mar 31 22:42:51 GMT 2025 , Edited by admin on Mon Mar 31 22:42:51 GMT 2025
|
PRIMARY | |||
|
m4836
Created by
admin on Mon Mar 31 22:42:51 GMT 2025 , Edited by admin on Mon Mar 31 22:42:51 GMT 2025
|
PRIMARY | Merck Index | ||
|
16357-59-8
Created by
admin on Mon Mar 31 22:42:51 GMT 2025 , Edited by admin on Mon Mar 31 22:42:51 GMT 2025
|
PRIMARY | |||
|
147831
Created by
admin on Mon Mar 31 22:42:51 GMT 2025 , Edited by admin on Mon Mar 31 22:42:51 GMT 2025
|
PRIMARY | |||
|
EEDQ
Created by
admin on Mon Mar 31 22:42:51 GMT 2025 , Edited by admin on Mon Mar 31 22:42:51 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
